MedTrace Logo

Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole

NCT00567099 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-05-25

No results posted yet for this study

Summary

The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia prior to initiation with aripiprazole treatment and after three months of taking the antipsychotic medication aripiprazole.

Conditions

Interventions

DRUG

Aripiprzole

Dosage form, dosage, frequency and duration: Aripiprazole 5-30 mg tabs po qday x 3 months

Sponsors & Collaborators

Principal Investigators

  • Jose M Canive, MD · New Mexico VA Healthcare System / BRINM

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-08-31
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00567099 on ClinicalTrials.gov